Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven G Reed

Showing results (121-130 of 263) with videos related to

Pageof 27
Sort By:
Vaccine|November 17, 2015
Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adultsMarilia Santini-Oliveira, Rhea N Coler, Juçara Parra, et al.
Scientific Reports|March 7, 2026
Junction opener enables CAR T cell treatment of solid tumorsSteven J Reed, Shibbu Sharma, Carrie Novák, et al.
Plos One|May 24, 2013
Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cellsKatie Matthews, Nancy P Y Chung, Per Johan Klasse, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 24, 2018
Computationally Designed Bispecific MD2/CD14 Binding Peptides Show TLR4 Agonist ActivityAmit Michaeli, Shaul Mezan, Andreas Kühbacher, et al.
Vaccine|September 26, 2016
Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvantRobert G Schaut, Tara L Grinnage-Pulley, Kevin J Esch, et al.
Plos One|January 28, 2014
Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimenPaul F McKay, Alethea V Cope, Jamie F S Mann, et al.
Plos One|July 26, 2012
Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140Mauricio A Arias, Griet A Van Roey, John S Tregoning, et al.
Vaccine|March 9, 2010
Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SEJoelma Trigo, Melissa Abbehusen, Eduardo M Netto, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 15, 2024
Preclinical development of lyophilized self-replicating RNA vaccines for COVID-19 and malaria with improved long-term thermostabilityGaurav K Gulati, Adrian C Simpson, Zachary MacMillen, et al.
Scientific Reports|October 31, 2019
Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse modelKee Woong Kwon, Ara Lee, Sasha E Larsen, et al.
Pageof 27

Showing results (121-130 of 263) with videos related to

Sort By:
Pageof 27
Vaccine|November 17, 2015
Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adultsMarilia Santini-Oliveira, Rhea N Coler, Juçara Parra, et al.
Scientific Reports|March 7, 2026
Junction opener enables CAR T cell treatment of solid tumorsSteven J Reed, Shibbu Sharma, Carrie Novák, et al.
Plos One|May 24, 2013
Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cellsKatie Matthews, Nancy P Y Chung, Per Johan Klasse, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 24, 2018
Computationally Designed Bispecific MD2/CD14 Binding Peptides Show TLR4 Agonist ActivityAmit Michaeli, Shaul Mezan, Andreas Kühbacher, et al.
Vaccine|September 26, 2016
Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvantRobert G Schaut, Tara L Grinnage-Pulley, Kevin J Esch, et al.
Plos One|January 28, 2014
Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimenPaul F McKay, Alethea V Cope, Jamie F S Mann, et al.
Plos One|July 26, 2012
Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140Mauricio A Arias, Griet A Van Roey, John S Tregoning, et al.
Vaccine|March 9, 2010
Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SEJoelma Trigo, Melissa Abbehusen, Eduardo M Netto, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 15, 2024
Preclinical development of lyophilized self-replicating RNA vaccines for COVID-19 and malaria with improved long-term thermostabilityGaurav K Gulati, Adrian C Simpson, Zachary MacMillen, et al.
Scientific Reports|October 31, 2019
Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse modelKee Woong Kwon, Ara Lee, Sasha E Larsen, et al.
Pageof 27